Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2024
Collet Clinical and Research from Pajottegem, company number BE0743459171, closed financial year 2024 with a result of € 91,001 after tax. For that financial year Collet Clinical and Research recorded a gross margin of € 147,169 and equity of € 183,556. Compared with financial year 2023, the result moved from € 143,723 to € 91,001. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 28, 2025.
€ 183,556
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 91,001
▼ 37% vs 2023
Profit after tax over the fiscal year.
€ 50,899
▲ 54% vs 2023
Cash and bank balances on the last day of the fiscal year.
€ 91,000 paid out
100 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2024
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 50,429
▼ 26% vs 2023
Book value of vehicles, furniture and equipment.
Debts at end 2024
€ 52,390
▼ 60% vs 2023
€ 29,040 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 439
▼ 97% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 35,496
▼ 42% vs 2023
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Gross margin | € 214,681 | € 291,252 | € 209,318 | € 147,169 | ▼ 30% |
| Profit after taxes | € 149,299 | € 217,517 | € 143,723 | € 91,001 | ▼ 37% |
| Equity | € 182,315 | € 182,832 | € 183,555 | € 183,556 | |
| Total debts | € 78,313 | € 435,138 | € 342,302 | € 164,581 | ▼ 52% |
| Cash | € 9,453 | € 67,903 | € 33,150 | € 50,899 | ▲ 54% |
| Retained profit | € 176,315 | € 176,832 | € 177,555 | € 177,556 | |
| Dividend | € 0 | € 217,000 | € 143,000 | € 91,000 | ▼ 36% |
| Bank debt | € 0 | € 93,680 | € 129,731 | € 52,390 | ▼ 60% |
| Balance sheet total | € 260,628 | € 617,970 | € 525,857 | € 348,137 | ▼ 34% |
Key figures of Collet Clinical and Research, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to Collet Clinical and Research?
What happened at Collet Clinical and Research in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: profit of € 91,001 (▼ 37% vs 2023). filed late Source: NBB ↗
- New establishment in Aalst. KBO
- Start of the company according to the CBE. KBO
In short
From € 149,299 profit in 2021 to € 91,001 profit in 2024.
Paid € 202,775 in corporate taxes since 2021.
Best year ever: 2022, with € 217,517 profit.
Paid out € 451,000 in dividends to the owners in total.
A new publication or filing at Collet Clinical and Research? We notify you, reason included.
Follow Collet Clinical and ResearchDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Collet Clinical and Research is Carlos Collet Bortone. Carlos Collet Bortone is also behind CoreAalst and ARTERIAX.
Establishments
Establishment units
Physical locations of this company
Hekstraat(HN) 28
1540 Pajottegem
Moorselbaan 164
9300 Aalst
Active since 10 February 2020
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0743.459.171
- VAT number
- BE 0743.459.171
- Registered office
- Hekstraat(HN) 28, 1540 Pajottegem
- Names & denominations
- Collet Clinical and Research
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 10 February 2020
- Peppol
- Not registered
- Activities · NACE
Activiteiten van medisch specialisten